BioMarin Pharmaceutical has announced the roll-out of the national phenylketonuria demographics, outcomes and safety registry.
The registry is open to all phenylketonuria (PKU) clinics within the US, and all patients screened for Kuvan responsiveness are eligible for enrollment in the registry.
Also, from September 1, 2008 until December 31, 2008, to facilitate enrollment in the registry, new patients at clinics participating in the registry will be able to receive 45 days of free drug while individual insurance coverage is secured.
Jean-Jacques Bienaime, CEO of BioMarin, said: “We are excited to initiate the first PKU patient registry and believe that it will substantially strengthen the available data on a variety of PKU patient populations, including some less studied, such as children under four years of age and maternal PKU patients.”
Comments